PURPOSE® Fireside: How a Blocked Merger Saved Novo Nordisk — and the $500B Lesson Behind Ozempic

Maike Kauffmann (Purpose Foundation) hosts a fireside with Eric on the structures that hold mission steady under systemic pressure. The recap leads with Novo Nordisk: a board of trustees blocked a 1990s merger because the ownership structure made protecting the mission non-negotiable — two years later the merger target was acquired and shut down, and Novo Nordisk went on to invent Ozempic and exceed Denmark's GDP in market cap.

“In the late 90s, a board of trustees blocked a merger that would have made everyone in the room very, very rich. Two years later, the company they were about to merge with was acquired and shut down. Meanwhile, the company they protected went on to invent Ozempic, a groundbreaking diabetes drug. From that blocked merger to the moment Novo Nordisk's market cap exceeded the GDP of Denmark: $500 billion in shareholder value created. Not just because someone (or some trustees in this case) said no. But because the ownership structure made protecting the mission non-negotiable, even when the "dump trucks of money" were pulling up outside.” — PURPOSE® on LinkedIn